AR and prostate carcinoma: This may provide an explanation to the discrepancies seen with NKX3.1’s role in early-stages of prostate cancer, given that factors like SOX2 are AR-repressed [25] and upregulated after androgen targeted therapy and promote therapeutic resistance [25,56,57,58].